. 2014 Sep 2;2(3):654–685. doi: 10.3390/vaccines2030654

Table 5.

Particulate-adjuvanted Schistosoma vaccine candidates classified as a function of the adjuvant.

Adjuvant	Administration	Antigen ^a	Reduction (%) ^b		References
Adjuvant	Administration	Antigen ^a	Eggs	Worms	References
QuilA	s.c	Sj97 pmy	32	66	[6,21,32]
	i.m	Sj97 pmy	34 (water buffalo)	48	[6,21,32]
	i.m	SjSVLBP	n.t	34	[18,48]
	i.m	Sj97	50–80	35–40	[24,25,49]
	s.c	SjASP	n.t	21–40	[3,18,50]
	i.p	SjLD2 SjIR	67	37–42	[5,51]
Liposome	i.t	SjGST1194	0	0	[52]
Liposome	orally	Sm28GST	53	52	[53]
PGN	s.c	SmESP	n.t	n.t	[26]
Vegetal polysaccharide	i.n	Pmy	n.t	40	[43]
Lewis X polysaccharide	i.n	LNFPIII	n.t	n.t	[29]
Poly(I:C)	s.c	SmESP	n.t	n.t	[26]
CpG ODN	?	Sm-p80	n.t (primates)	58	[54,55]
LCP	i.p	Sm-CatD	n.t	n.t	[20,32]
R-848	i.m	Sm-p80	100	70	[5,56]
R-848	?	Sm-p80	n.t (primates)	52	[54]

^a Current vaccine candidates include Sj/SmTPI, Sj/Sm pmy, Sh28GST, Sm14, Sm-tsp-2, SjIR, Sj/Sm23 [3]; ^b Experimental data acquired in mice/rats unless specified; Abbreviations: n.t: not tested; i.m: intramuscular; s.c: subcutaneous; i.p: intraperitoneal; i.t: intratracheal instillation; LCP: Lipid core peptide; QuilA: saponin; R-848: resiquimod; Pmy: paramyosin; PGN: peptidoglycan; poly(I:C): polyinosinic:polycytidylic acid.